Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 9/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28950613 | 0.81 | NPC1 (0.49) | CYP2C9CYP2C19NPSR1TP53MAPT | |
| SCHEMBL160032 | 0.79 | TP53 (0.51) | CYP2C19NPSR1TP53MAPTHSD17B10 | |
| SCHEMBL18527352 | 0.75 | CYP2C9 (0.38) | CYP2C9CYP2C19NPSR1GABRG2GABRB3 | |
| SCHEMBL163839 | 0.74 | CA12 (0.43) | CYP2C9CYP2C19TP53MAPTHSD17B10 | |
| SCHEMBL162619 | 0.74 | CYP1A2 (0.50) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL164388 | 0.71 | ALDH1A1 (0.49) | NPSR1GABRG2GABRB3GABRA1GABRA2 | |
| SCHEMBL163576 | 0.70 | MAPT (0.40) | TP53MAPTNPC1RAB9A | |
| SCHEMBL162738 | 0.70 | MAPK1 (0.44) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL31124076 | 0.70 | MAPT (0.48) | CYP2C9CYP2C19NPSR1MAPT | |
| SCHEMBL15205035 | 0.70 | TSHR (0.50) | NPSR1TP53MAPTHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | CYP2C9 3870/4885CYP2C19 4178/4885NPSR1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.